文献速递糖尿病

利拉鲁肽对比安慰剂对2型糖尿病心血管高危患者急性胆囊或胆道疾病事件的影响:LEADER随机试验

Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial.
PubMed 文献 · Diabetes Care · 2019-08-09

LEADER试验事后分析纳入9340例心血管高危的2型糖尿病患者,随机接受利拉鲁肽(≤1.8 mg/日)或安慰剂。利拉鲁肽组急性胆囊或胆道疾病风险高于安慰剂组(HR 1.60,95%CI 1.23-2.09,P<0.001),胆囊切除术也更常见(HR 1.56,95%CI 1.10-2.20,P=0.013)。

要点

  • 利拉鲁肽增加急性胆囊或胆道疾病风险(HR 1.60,95%CI 1.23-2.09)。
  • 四类胆囊/胆道事件均呈相似趋势。
  • 胆囊切除术在利拉鲁肽组更常见(HR 1.56,95%CI 1.10-2.20)。

核心结论

  • 利拉鲁肽对比安慰剂增加2型糖尿病心血管高危患者急性胆囊或胆道疾病事件风险,四类事件趋势一致,需进一步研究机制。

研究设计与样本

  • LEADER为国际、随机、双盲、对照心血管结局试验,纳入9340例心血管高危的2型糖尿病患者,1:1随机接受利拉鲁肽(≤1.8 mg/日,n=4668)或安慰剂(n=4672),均接受标准治疗,治疗期3.5-5年。

主要发现

  • 利拉鲁肽组141/4668例 vs 安慰剂组88/4672例发生急性胆囊或胆道疾病(HR 1.60;95%CI 1.23,2.09;P<0.001)。
  • 四类胆囊或胆道相关事件(非复杂性胆囊结石、复杂性胆囊结石、胆囊炎、胆道梗阻)均观察到相似趋势。
  • 胆囊切除术在利拉鲁肽组更频繁(HR 1.56;95%CI 1.10,2.20;P=0.013),但在发生胆囊或胆道事件的患者中比例相似(利拉鲁肽57% vs 安慰剂59%)。

临床怎么用

  • 对心血管高危的2型糖尿病患者使用利拉鲁肽时,应关注急性胆囊或胆道疾病风险,尤其需警惕胆囊切除术可能。

局限性

  • LEADER并非专门设计评估急性胆囊或胆道疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore gallbladder- and biliary tract-related events reported for the liraglutide and placebo groups in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. RESEARCH DESIGN AND METHODS: LEADER was an international, randomized, double-blind, controlled cardiovascular (CV) outcomes trial. Participants with type 2 diabetes at high risk for CV events (n = 9,340) were randomized 1:1 to receive either liraglutide (≤1.8 mg daily; n = 4,668) or placebo (n = 4,672), with both groups also receiving standard care (treatment period: 3.5-5 years). Acute gallstone disease was a medical event of special interest. This post hoc analysis categorized captured events of acute gallbladder or biliary disease into four groups: uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis, and biliary obstruction. Time to first event by treatment group was analyzed using Cox regression. RESULTS: There was an increased risk of acute gallbladder or biliary disease with liraglutide versus placebo (n = 141 of 4,668 vs. n = 88 of 4,672 patients, respectively; hazard ratio [HR] 1.60; 95% CI 1.23, 2.09; P < 0.001). Similar trends were observed for each of the four categories of gallbladder- or biliary tract-related events. Cholecystectomy was performed more frequently in liraglutide-treated patients (HR 1.56; 95% CI 1.10, 2.20; P = 0.013) but for similar proportions of the patients who experienced gallbladder- or biliary tract-related events (57% with liraglutide vs. 59% with placebo). CONCLUSIONS: Although LEADER was not specifically designed to assess acute gallbladder or biliary disease, the trial showed an increased risk of gallbladder- or biliary tract-related events with liraglutide versus placebo, which appeared to be consistent across four categories of these events. Further studies should investigate the relevant mechanisms.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019. PMID: 31399438. doi:10.2337/dc19-0415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。